<h4>Background</h4>This study aimed to systematically evaluate and compare the efficacy and safety of consolidative hematopoietic stem cell transplantation (HSCT) after CD19 chimeric antigen receptor T (CAR-T) therapy with non-HSCT in the treatment of acute lymphoblastic leukemia (ALL).<h4>Methods</h4>The PubMed, Embase, Cochrane Library and Web of Science databases were searched for clinical trials. Here, CD19 is linked to acute lymphoblastic leukemia.